The content, links, and pdfs are no longer maintained and might be outdated.
- The content on this page is being archived for historic and reference purposes only.
- For current, updated information see the MMWR website.
Erratum: Vol. 59, No. RR-8
In the MMWR Recommendations and Reports "Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010," on page 18, the first two sentences under the heading "Pregnant Women and Neonates" should read, "FDA has classified FluLaval, Fluarix (GlaxoSmithKline Biologicals), and Agriflu (Novartis Vaccines and Diagnostics Limited) influenza vaccines as "Pregnancy Category B" medications, indicating that animal reproduction studies have not demonstrated a fetal risk, but there are no controlled studies in pregnant women; all other influenza vaccines are classified as "Pregnancy Category C" medications, indicating that adequate animal reproduction studies have not been conducted. Available data do not indicate that any influenza vaccine causes fetal harm when administered to a pregnant woman, and any of the approved TIV formulations may be used for vaccinating pregnant women."
All MMWR HTML versions of articles are electronic conversions from typeset documents.
This conversion might result in character translation or format errors in the HTML version.
Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr)
and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S.
Government Printing Office (GPO), Washington, DC 20402-9371;
telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to email@example.com.